Dr. Anne Tsao of MD Anderson discusses her approach to treating non small cell lung cancer.
Description: There is a paradigm shift in the treatment of metastatic NSCLC that involves the targeted therapies and histologic subtype. In SCC patients, front-line systemic therapy should avoid the use of bevacizumab and pemetrexed. In non-SCC patients, there are several options. In patients with sensitive EGFR mutations, I recommend front-line EGFR TKI therapy. Patients who are minimal former or never smokers that are EGFR wild-type may carry the EML 4-ALK fusion protein, and crizotinib, an ALK inhibitor, provides significant clinical benefit. In patients who are wild-type for EGFR and do not carry the EML 4 ALK fusion, they may receive bevacizumab based therapy or a chemotherapy doublet regimen. This video blog reviews the treatment algorithm for patients with NSCLC.
Shared By : videoblog
Posted on : 08/25/10
Added : 8 years ago